Compare Abbott India with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs SUVEN LIFESCIENCES - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA SUVEN LIFESCIENCES ABBOTT INDIA/
SUVEN LIFESCIENCES
 
P/E (TTM) x 43.1 20.4 211.1% View Chart
P/BV x 12.3 4.1 298.4% View Chart
Dividend Yield % 0.6 0.5 109.7%  

Financials

 ABBOTT INDIA   SUVEN LIFESCIENCES
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
SUVEN LIFESCIENCES
Mar-19
ABBOTT INDIA/
SUVEN LIFESCIENCES
5-Yr Chart
Click to enlarge
High Rs6,110338 1,809.3%   
Low Rs3,996169 2,358.9%   
Sales per share (Unadj.) Rs1,552.252.1 2,977.7%  
Earnings per share (Unadj.) Rs188.86.8 2,764.1%  
Cash flow per share (Unadj.) Rs196.48.6 2,291.9%  
Dividends per share (Unadj.) Rs55.001.50 3,666.7%  
Dividend yield (eoy) %1.10.6 184.0%  
Book value per share (Unadj.) Rs796.665.3 1,220.1%  
Shares outstanding (eoy) m21.25127.28 16.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.34.9 66.9%   
Avg P/E ratio x26.837.1 72.1%  
P/CF ratio (eoy) x25.729.6 87.0%  
Price / Book Value ratio x6.33.9 163.3%  
Dividend payout %29.122.0 132.7%   
Avg Mkt Cap Rs m107,37632,272 332.7%   
No. of employees `0003.31.1 307.0%   
Total wages/salary Rs m3,937661 595.4%   
Avg. sales/employee Rs Th9,929.36,132.2 161.9%   
Avg. wages/employee Rs Th1,185.1611.1 193.9%   
Avg. net profit/employee Rs Th1,207.7803.5 150.3%   
INCOME DATA
Net Sales Rs m32,9856,635 497.1%  
Other income Rs m1,170242 482.9%   
Total revenues Rs m34,1556,877 496.6%   
Gross profit Rs m5,2451,604 327.0%  
Depreciation Rs m162221 73.1%   
Interest Rs m3838 101.3%   
Profit before tax Rs m6,2151,587 391.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,203718 306.8%   
Profit after tax Rs m4,012869 461.5%  
Gross profit margin %15.924.2 65.8%  
Effective tax rate %35.445.2 78.4%   
Net profit margin %12.213.1 92.8%  
BALANCE SHEET DATA
Current assets Rs m22,6556,232 363.5%   
Current liabilities Rs m6,6811,490 448.3%   
Net working cap to sales %48.471.5 67.8%  
Current ratio x3.44.2 81.1%  
Inventory Days Days6586 74.9%  
Debtors Days Days2983 35.3%  
Net fixed assets Rs m8354,043 20.7%   
Share capital Rs m213127 166.9%   
"Free" reserves Rs m16,7158,183 204.3%   
Net worth Rs m16,9288,310 203.7%   
Long term debt Rs m018 0.0%   
Total assets Rs m24,16210,389 232.6%  
Interest coverage x163.743.1 379.7%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.40.6 213.8%   
Return on assets %16.88.7 192.0%  
Return on equity %23.710.5 226.5%  
Return on capital %36.919.5 189.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3695,622 6.6%   
Fx outflow Rs m3,8071,799 211.5%   
Net fx Rs m-3,4383,822 -89.9%   
CASH FLOW
From Operations Rs m1,527356 429.5%  
From Investments Rs m-2,148-279 771.1%  
From Financial Activity Rs m-1,024-225 455.0%  
Net Cashflow Rs m-1,646-148 1,110.4%  

Share Holding

Indian Promoters % 0.0 63.4 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 0.0 -  
FIIs % 0.1 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 36.5 46.8%  
Shareholders   18,270 37,287 49.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   ORCHID PHARMA LTD  WYETH LTD  TORRENT PHARMA  UNICHEM LAB  DR. REDDYS LAB  

Compare ABBOTT INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Oil & Gas and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended lower. At the closing bell, the BSE Sensex stood lower by 262 points (down 0.7%).

Related Views on News

ABBOTT INDIA at All Time High; BSE HEALTHCARE Index Up 0.4% (Market Updates)

Sep 16, 2019 | Updated on Sep 16, 2019

ABBOTT INDIA share price has hit an all time high at Rs 10,015 (up 1.5%). The BSE HEALTHCARE Index is up by 0.4%. Among the top gainers in the BSE HEALTHCARE Index today are ABBOTT INDIA (up 1.5%) and PROCTER & GAMBLE HEALTH (up 1.2%). The top losers include NATCO PHARMA (down 0.2%) and BIOCON (down 0.2%).

SUVEN LIFESCIENCES Surges by 5%; BSE HEALTHCARE Index Up 0.5% (Market Updates)

Sep 16, 2019 | Updated on Sep 16, 2019

SUVEN LIFESCIENCES share price has surged by 5% and its current market price is Rs 294. The BSE HEALTHCARE is up by 0.5%. The top gainers in the BSE HEALTHCARE Index are SUVEN LIFESCIENCES (up 5.2%) and WOCKHARDT (up 7.4%). The top losers are AJANTA PHARMA and PIRAMAL ENTERPRISES (down 0.2%).

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Sep 16, 2019 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - DISHMAN PHARMA COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS